2. Трухан Д.И., Чуянова Ю.С., Макушин Д.Г. Проблема недержания мочи сквозь призму коморбидности. Клинический разбор в общей медицине. 2021; (9): 11–23. (Trukhan D.I., Chuyanova Yu.S., Makushin D.G. The problem of urinary incontinence through the prism of comorbidity. Klinicheskiy razbor v obshchey meditsine = Clinical review for general practice. 2021; (9): 11–23 (In Russ.)).

https://doi.org/10.47407/kr2021.2.9.00103. EDN: PKEDUR.

3. Мазо Е.Б., Кривобородов Г.Г. Гиперактивный мочевой пузырь. М.: Вече. 2003; 160 с. (Mazo E.B., Krivoborodov G.G. Hyperactive bladder. Moscow: Veche. 2003; 160 pp. (In Russ.)). ISBN: 5-9533-0122-7. EDN: QLESAZ.

4. Lukacz E.S., Santiago-Lastra Y., Albo M.E., Brubaker L. Urinary incontinence in women: A review. JAMA. 2017; 318(16): 1592–1604.

https://dx.doi.org/10.1001/jama.2017.12137. PMID: 29067433.

5. Кривобородов Г.Г., Тур Е.И., Ширин Д.А. Гиперактивный мочевой пузырь: концепция заболевания и подходы к лечению. Медицинский совет. 2021; (4): 121–126. (Krivoborodov G.G., Tur E.I., Shirin D.A. Hyperactive bladder: Concept of disease and paradigms in the treatment. Meditsinskiy sovet = Medical Council. 2021; (4): 121–126 (In Russ.)).

https://doi.org/10.21518/2079-701X-2021-4-121-126. EDN: XTOBZY.

6. Stewart W.F., Van Rooyen J.B., Cundiff G.W. et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003; 20(6): 327–36.

https://doi.org/10.1007/s00345-002-0301-4. PMID: 12811491.

7. Irwin D.E., Milsom I., Hunskaar S. et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol. 2006; 50(6): 1306–14.

https://doi.org/10.1016/j.eururo.2006.09.019. PMID: 17049716.

8. Трухан Д.И., Филимонов С.Н. Дифференциальный диагноз основных симптомов и синдромов при заболеваниях почек и мочевых путей. Учебное пособие. Новокузнецк: ООО «Полиграфист». 2018; 239 с. (Trukhan D.I., Filimonov S.N. Differential diagnosis of the main symptoms and syndromes in kidney and urinary tract diseases. The training manual. Novokuznetsk: Polygraphist LLC. 2018; 239 pp. (In Russ.)). ISBN: 978-5-91797-263-3. EDN: XWNAQX.

9. Furukawa S., Sakai T., Niiya T. et al. Macrovascular complications and prevalence of urgency incontinence in Japanese patients with type 2 diabetes mellitus: The Dogo Study. Intern Med. 2017; 56(8): 889–93.

https://doi.org/10.2169/internalmedicine.56.8063. PMID: 28420835. PMCID: PMC5465403.

10. Michel M.C., Chapple C.R. Basic mechanisms of urgency: Preclinical and clinical evidence. Eur Urol. 2009; 56(2): 298–307.

https://doi.org/10.1016/j.eururo.2009.05.028. PMID: 19523751.

11. Cucchi A., Quaglini S., Rovereto B. Relationships between micturition urgency and involuntary voiding dynamics in men with urinary incontinence from idiopathic detrusor overactivity. J Urol. 2007; 178(2): 563–67.

https://doi.org/10.1016/j.juro.2007.03.122. PMID: 17570436.

12. Cucchi A., Quaglini S., Siracusano S., Rovereto B. Urgency degree and bladder contraction velocity: Sequential changes in women with idiopathic detrusor overactivity. Neurourol Urodyn. 2006; 25(2): 123–27.

https://doi.org/10.1002/nau.20217. PMID: 16381021.

13. Akbar A., Liu K., Michos E.D. et al. Association of overactive bladder with hypertension and blood pressure control: The Multi-Ethnic Study of Atherosclerosis (MESA). Am J Hypertens. 2022; 35(1): 22–30.

https://doi.org/10.1093/ajh/hpaa186. PMID: 33899909. PMCID: PMC8730485.

14. Garvey W.T., Garber A.J., Mechanick J.I. et al.; The Aace Obesity Scientific Committee American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014; 20(9): 977–89.

https://doi.org/10.4158/EP14280.PS. PMID: 25253227. PMCID: PMC4962331.

15. Del Popolo G., Panariello G., Del Corso F. et al. Diagnosis and therapy for neurogenic bladder dysfunctions in multiple sclerosis patients. Neurol Sci. 2008. 29 Suppl 4: S352–5.

https://doi.org/10.1007/s10072-008-1042-y. PMID: 19089675.

16. Cameron A.P., Rodriguez G.M., Gursky A. et al. The severity of bowel dysfunction in patients with neurogenic bladder. J Urol. 2015; 194(5): 1336–41.

https://doi.org/10.1016/j.juro.2015.04.100. PMID: 25956470.

17. Game X., Phe V. Pathophysiology of overactive bladder. Prog Urol. 2020; 30(14): 873–79.

https://doi.org/10.1016/j.purol.2020.08.003. PMID: 33220815.

18. Irwin D., Milsom I., Kopp Z. et al. Overactive bladder symptom prevalence and healthcare – seeking behaviour among men in 6 European countries. European Urol Suppl. 2005; 4(3): 60.

http://dx.doi.org/10.1016/S1569-9056(05)80238-6.

19. Milsom I., Abrams P., Cardoso L. et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001; 87(9): 760–66.

https://doi.org/10.1046/j.1464-410x.2001.02228.x. PMID: 11412210.

20. Nambiar A.K., Bosch R., Cruz F. et al. EAU Guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol. 2018; 73(4): 596–609.

https://doi.org/10.1016/j.eururo.2017.12.031. PMID: 29398262.

21. Gacci M., Sakalis V.I., Karavitakis M. et al. European Association of Urology guidelines on male urinary incontinence. Eur Urol. 2022; 82(4): 387–98.

https://doi.org/10.1016/j.eururo.2022.05.012. PMID: 35697561.

22. Bryant C.M., Dowell C.J., Fairbrother G. Caffeine reduction education to improve urinary symptoms. Br J Nurs. 2002; 11(8): 560–65.

https://doi.org/10.12968/bjon.2002.11.8.10165. PMID: 11979209.

23. Murgas S., Adolf D. Evaluation of real-world persistence of propiverine and trospium chloride in treatment of overactive bladder in Germany. Res Rep Urol. 2019; 11: 9–13.

https://dx.doi.org/10.2147/RRU.S185278. PMID: 30697533. PMCID: PMC6342142.

24. Natalin R., Lorenzetti F., Dambros M. Management of OAB in those over age 65. Curr Urol Rep. 2013; 14(5): 379–85.

https://dx.doi.org/10.1007/s11934- 013-0338-5. PMID: 23922134.

25. Ikeda K., Kobayashi S., Suzuki M. et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn-Schmiedebergs Arch Pharmacol. 2002; 366(2): 97–103.

https://doi.org/10.1007/s00210-002-0554-x. PMID: 12122494.

26. Reynolds W.S., McPheeters M., Blume J. et al. Comparative effectiveness of anticholinergic therapy for overactive bladder in women: A systematic review and meta-analysis. Obstet Gynecol. 2015; 125(6): 1423–32.

https://doi.org/10.1097/aog.0000000000000851. PMID: 26000514.

27. Duong V., Iwamoto A., Pennycuff J. et al. A systematic review of neurocognitive dysfunction with overactive bladder medications. Int Urogynecol J. 2021; 32(10): 2693–2702.

https://doi.org/10.1007/s00192-021-04909-5. PMID: 34213600.

28. Staskin D., Kay G., Tannenbaum C. et al. Trospium chloride is undetectable in the older human central nervous system. J Am Geriatr Soc. 2010; 58(8): 1618–19.

https://doi.org/10.1111/j.1532-5415.2010.02988.x. PMID: 20942892.

29. Buser N., Ivic S., Kessler T.M. et al. Efficacy and adverse events of antimuscarinics for treating overactive bladder: Network meta-analyses. Eur Urol. 2012; 62(6): 1040–60.

https://doi.org/10.1016/j.eururo.2012.08.060. PMID: 22999811.

30. Kranz J., Petzinger E., Geyer J. Brain penetration of the OAB drug trospium chloride is not increased in aged mice. World J Urol. 2013; 31(1): 219–24.

https://doi.org/10.1007/s00345-011-0803-z. PMID: 22120415. PMCID: PMC3557395.

31. Коршунова Е.С., Коршунов М.Н., Нужный Е.П. с соавт. Нейрогенный гиперактивный мочевой пузырь: фокус на когнитивную функцию. Урология. 2021; (5): 35–40. (Korshunova E.S., Korshunov M.N., Nuzhnyi E.P. et al. Neurogenic overactive bladder: focus on cognitive function. Urologiya = Urology. 2021; (5): 35–40 (In Russ.)).

https://doi.org/10.18565/urology.2021.5.35-40. EDN: AXPPZP.

32. Котовская Ю.В., Остапенко В.С., Ткачева О.Н. Сохранение когнитивных функций у пациентов пожилого возраста: важность гериатрического подхода. Справочник поликлинического врача. 2017; (5): 15–19. (Kotovskaya Yu.V., Ostapenko V.S., Tkacheva O.N. Preservation of cognitive functions in elderly patients: The importance of the geriatric approach. Spravochnik poloklinicheskogo vracha = Clinician’s Reference Book. 2017; (5): 15–19 (In Russ.)). EDN: QGXZQX.

33. Doroshyenko O., Jetter A., Odenthal K.P., Fuhr U. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet. 2005; 44(7): 701–20.

https://doi.org/10.2165/00003088-200544070-00003. PMID: 15966754.

34. Biastre K., Burnakis T. Trospium chloride treatment of overactive bladder. Ann Pharmacother. 2009; 43(2): 283–95.

https://doi.org/10.1345/aph.1L160. PMID: 19193592.

35. Chapple C. New once-daily formulation for trospium in overactive bladder. Int J Clin Pract. 2010; 64(11): 1535–40.

https://doi.org/10.1111/j.1742-1241.2010.02493.x. PMID: 20846201.

36. Кульчавеня Е.В., Холтобин Д.П. Гиперактивный мочевой пузырь у сложного пациента: какой препарат выбрать? Урология. 2021; (1): 120–125. (Kulchavenya E.V., Kholtobin D.P. Overactive bladder in a complicated patient: Which drug to choose? Urologiya = Urology. 2021; (1): 120–125 (In Russ.)).

https://dx.doi.org/10.18565/urology.2021.1.120-125. EDN: XCGKDU.

37. Данилов В.В., Вольных И.Ю. Обоснование назначения троспия хлорида в первой линии терапии при гиперактивном мочевом пузыре. Фарматека. 2023; 30(1–2): 226–231. (Danilov V.V., Volnykh I.Yu. Rationale for the use of trospium chloride in the first line of therapy for overactive bladder. Farmateka. 2023; 30(1–2): 226–231 (In Russ.)).

https://dx.doi.org/10.18565/pharmateca.2023.1-2.226-230. EDN: DBGIEY.

38. Кульчавеня Е.В. Постковидный синдром в урологии. Клинический разбор в общей медицине. 2022; (4): 66–72. (Kulchavenya E.V. Post-covid syndrome in urology. Klinicheskiy razbor v obshchey meditsine = Clinical review for general practice. 2022; (4): 66–72 (In Russ.)).

https://doi.org/10.47407/kr2022.3.4.00154. EDN: GEELUA.

39. Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению лекарственного препарата Спазмекс®. РУ: ЛП-№(007599)-(РГ-RU) от 08.11.2024. Доступ: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=075672cd-4b84-45a1-b29e-cbba73f6a7e7 (дата обращения – 12.02.2025). (State register of medicines of the Ministry of Healthcare of Russia. Instructions for medical use of the drug Spasmex®. Registration certificate: ЛП-№(007599)-(РГ-RU) from 11/08/2024. URL: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=075672cd-4b84-45a1-b29e-cbba73f6a7e7 (date of access – 12.02.2025) (In Russ.)).

40. Кривобородов Г.Г., Тур Е.И., Ефремов Н.С., Школьников М.Е. Высокие дозы троспия хлорида у больных с гиперактивным мочевым пузырем вследствие неврологических заболеваний. Данные мультицентровой наблюдательной программы РЕСУРС. Consilium Medicum. 2015; 17(12): 64–67. (Krivoborodov G.G., Tur E.I., Efremov N.S., Shkolnikov M.E. High doses of trospium chloride in patients with overactive bladderdue to neurologic disease. The multicenter observational program resource. Consilium Medicum. 2015; 17(12): 64–67 (In Russ.)). EDN: VIMUTT.

41. Коровина Н.А., Захарова И.Н., Мумладзе Э.Б. с соавт. Современные подходы к лечению инфекции мочевой системы у детей. Педиатрия. Consilium Medicum. 2004; (1): 33–38. (Korovina N.A., Zakharova I.N., Mumladze E.B. et al. Modern approaches to the treatment of urinary tract infections in children. Pediatriya. Consilium Medicum = Pediatrics. Consilium Medicum. 2004; (1): 33–38 (In Russ.)). EDN: OFFWLJ.

42. Школьников М.Е., Кривобородов Г.Г., Лучинский С.А. с соавт. Роль троспия хлорида в лечении женщин с синдромом гиперактивного мочевого пузыря. Гинекология. 2012; 14(4): 83–86. (Shkolnikov M.E., Krivoborodov G.G., Luchinsky S.A. et al. The role of trospium chloride in the treatment of women with overactive bladder syndrome. Ginekologiya = Gynecology. 2012; 14(4): 83–86 (In Russ.)). EDN: PDBROJ.

43. MacDiarmid S.A., Ellsworth P.I., Ginsberg D.A. et al. Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder. Urology. 2011; 77(1): 24–29.

https://doi.org/10.1016/j.urology.2010.07.469. PMID: 20970833.

44. Kosilov K., Loparev S., Kuzina I. et al. The effective tool for self-assessment of adherence to treatment in patients with benign prostatic obstruction and overactive bladder symptoms. Aging Male. 2017; 20(1): 39–44.

https://doi.org/10.1080/13685538.2016.1247435. PMID: 28074677.